Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease. April 20, 2021 ARTICLE CITATION DOI: 10.1200/JCO.21.00214 Journal of Clinical Oncology - published online before print April 20, 2021 PMID: 33877859 Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK Corey Cutler , MD, MPH1xCorey CutlerSearch for articles by this author Show More 1Dana-Farber Cancer Institute, Boston, MA https://doi.org/10.1200/JCO.21.00214 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyAUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTTreating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCKThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Corey CutlerStock and Other Ownership Interests: Bluebird Bio, Idera, Verastem, Northwest Biotherapeutics, Actinium PharmaceuticalsHonoraria: Omeros, PfizerConsulting or Advisory Role: Incyte, Jazz Pharmaceuticals, CareDX, Mesoblast, Syndax, MedsenicNo other potential conflicts of interest were reported. Companion ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease